Discover
TD-1473 / J&JTD-1473: Data from P2 DIONE trial (NCT03635112) for Crohn’s disease in 2020 or later (Theravance, SVB Leerink 9th Annual Global Healthcare Conference) - Feb 27, 2020 - Data from P2b/3 RHEA trial (NCT03758443) for ulcerative colitis in 2020 or later [Screenshot]Stelara (ustekinumab) / J&JREScUE: Loss of RESponse to Ustekinumab Treated by Dose Escalation (clinicaltrials.gov) - Feb 25, 2020 - P3; N=108; Recruiting; Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW; Not yet recruiting --> Recruitingozanimod (RPC1063) / BMSEfficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease (clinicaltrials.gov) - Feb 26, 2020 - P2; N=69; Completed; Sponsor: Celgene; Active, not recruiting --> CompletedEntyvio SC (vedolizumab SC) / TakedaTakeda receives positive CHMP opinion for subcutaneous formulation of vedolizumab for use as maintenance therapy in adults with moderately to severely active ulcerative colitis or Crohn’s disease (Businesswire) - Feb 28, 2020 - "Takeda Pharmaceutical Company Limited...announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a subcutaneous (SC) formulation of...vedolizumab for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). Takeda proposes to make vedolizumab SC available in both a pre-filled syringe and a pre-filled pen."
